NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $3.86 -0.02 (-0.52%) Closing price 04:00 PM EasternExtended Trading$3.85 -0.01 (-0.26%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Myriad Genetics Stock (NASDAQ:MYGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Myriad Genetics alerts:Sign Up Key Stats Today's Range$3.75▼$4.0950-Day Range$2.86▼$6.3152-Week Range$2.74▼$8.59Volume2.05 million shsAverage Volume1.74 million shsMarket Capitalization$369.21 millionP/E RatioN/ADividend YieldN/APrice Target$3.12Consensus RatingReduce Company Overview Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests designed to help healthcare providers assess disease risk, guide treatment decisions and support personalized care. The company serves physicians, health systems, pharmaceutical companies and patients, with a focus on areas including hereditary cancer, precision oncology, pharmacogenomics and women’s health. Its portfolio includes hereditary cancer testing, such as MyRisk, and oncology tests that analyze tumor biology to help inform treatment planning. Myriad also offers GeneSight, a pharmacogenomic test intended to help clinicians evaluate how a patient’s genetic profile may affect responses to certain psychiatric medications, along with other testing services related to reproductive and prenatal health. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad became widely known for its work identifying and testing BRCA1 and BRCA2 gene mutations. The company expanded its capabilities through acquisitions, including the 2016 purchase of Assurex Health, which developed GeneSight. Myriad’s testing services are primarily used in the United States and are also available in selected international markets. Nicole Lambert serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Myriad Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreMYGN MarketRank™: Myriad Genetics scored higher than 22% of companies evaluated by MarketBeat, and ranked 825th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.8 / 5Analyst RatingReduce Consensus RatingMyriad Genetics has received a consensus rating of Reduce. The company's average rating score is 1.57, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 3 sell ratings.Downside RiskMyriad Genetics has a consensus price target of $3.12, representing about 19.2% downside from its current price of $3.86.Amount of Analyst CoverageMyriad Genetics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Myriad Genetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.99) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.36% of the float of Myriad Genetics has been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Myriad Genetics has recently increased by 2.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.57 News SentimentMyriad Genetics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Myriad Genetics this week, compared to 4 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders1.90% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Stock News HeadlinesMyriad Genetics Names Sikri Commercial EVP; Reaffirms 2026 Guidance4 hours ago | rttnews.comMyriad Genetics Appoints Vishal Sikri Executive Vice President - CommercialSeptember 16 at 8:00 AM | globenewswire.comJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2 trillion, with Anthropic and OpenAI preparing IPOs of their own. But Najarian's top pick isn't an IPO. It's a small American company with a $6 billion market cap powering Elon Musk's newest venture, dubbed the Infinite Power Grid. The full story is laid out in his newly released presentation.September 16 at 1:00 AM | Banyan Hill Publishing (Ad)Myriad Genetics consensus price target lowered by 16.18% to $3.43September 16 at 5:35 AM | msn.com2 Unprofitable Stocks to Research Further and 1 We Find RiskySeptember 15 at 2:05 PM | finance.yahoo.comMyriad Genetics (MYGN) Gets a Hold from UBSSeptember 11, 2026 | theglobeandmail.comUBS Group Begins Coverage on Myriad Genetics (NASDAQ:MYGN)September 11, 2026 | americanbankingnews.comUBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral RatingSeptember 9, 2026 | marketscreener.comMSee More Headlines MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $6.15 on January 1st, 2026. Since then, MYGN stock has decreased by 37.2% and is now trading at $3.86. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.19. The firm's revenue was down 10.5% compared to the same quarter last year. Read the conference call transcript. Does Myriad Genetics have any subsidiaries? The following companies are subsidiaries of Myriad Genetics: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and others. Who are Myriad Genetics' major shareholders? Top institutional shareholders of Myriad Genetics include BlackRock Inc. (11.39%), Connor Clark & Lunn Investment Management Ltd. (1.47%), Assenagon Asset Management S.A. (1.09%) and Man Group plc (0.95%). Insiders that own company stock include Paul J Diaz, Samraat S Raha, Richard Bryan Riggsbee, S Louise Phanstiel, Rashmi Kumar, Heinrich Dreismann, Paul Bisaro, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX). Company Calendar Last Earnings7/30/2026Today9/16/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MYGN's financial health is in the Red zone, according to TradeSmith. MYGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Price Target for Myriad Genetics$3.12 High Price Target$4.00 Low Price Target$2.00 Potential Upside/Downside-19.2%Consensus RatingReduce Rating Score (0-4)1.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$365.90 million Net Margins-13.96% Pretax Margin-13.86% Return on Equity-16.09% Return on Assets-8.10% Debt Debt-to-Equity Ratio0.40 Current Ratio2.21 Quick Ratio1.98 Sales & Book Value Annual Sales$824.50 million Price / Sales0.45 Cash Flow$3.82 per share Price / Cash Flow1.01 Book Value$3.95 per share Price / Book0.98Miscellaneous Outstanding Shares95,650,000Free Float93,833,000Market Cap$369.21 million OptionableOptionable Beta1.68 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:MYGN) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
